Costigan et al. reported recurrence rate of 30% for FIGO stage IA tumours with CTNNB1 mutation in exon 3 in comparison to no recurrence in same stage tumours with wild-type CTNNB1. Also, 40% of recurrent tumours already metastasized to the lungs [49]. Here, CTNNB1 is linked to neoplasm.